Pediatric Thyroid Cancer: Practice Essentials, Epidemiology – Medscape Reference

Medscape
Univadis
Medscape
Univadis
No Results
No Results
processing….

Although a review of the literature contains numerous reports on the subject of pediatric thyroid carcinoma, the low incidence and subsequent lack of prospective randomized trials make drawing absolute conclusions regarding the definitive workup, management, and treatment of this disease difficult. In 2015, however, a task force commissioned by the American Thyroid Association (ATA), following an extensive literature search, issued the first guidelines on the management of pediatric thyroid nodules and differentiated thyroid cancer. [1, 2, 3]
A detailed understanding of how to perform a comprehensive evaluation of the pediatric thyroid nodule and persistent cervical adenopathy is necessary in order to establish the diagnosis of pediatric thyroid cancer. Based on retrospective series, the prevalence of thyroid nodules in children ranges from 0.2-5%, compared with approximately 30% in adults. However, pediatric thyroid nodules carry a far greater risk of harboring malignancy compared with adults, at approximately 26.4%. Some authors have reported an incidence of as high as 36%. [4] Because pediatric thyroid nodules carry this increased risk of malignancy, physicians should perform an expeditious workup. [5, 6]
Thyroid carcinoma in pediatric patients usually manifests as an asymptomatic neck mass, with a reported incidence of cervical lymphadenopathy ranging from 35-83%. [7] The neck masses are typically discovered incidentally by parents or patients or by physicians during routine physical examination. Focal fold paralysis in children with thyroid malignancy is much less common than in adults with thyroid malignancy. [8]
Additionally, unlike adults, young patients with thyroid nodules often do not report pain, tenderness, compression of the respiratory tract, problems with swallowing, or inappropriate fixation of the neck. Even young patients who have lung metastases usually do not report pulmonary symptoms. [9] However, 10-20% of patients present with distant metastasis (most commonly to the lungs), and 70% of patients present with extensive regional nodal involvement. [10]
The recommended diagnostic protocol of thyroid nodules consists of the following steps:
Child’s history, including familial history and radiation exposure
Clinical examination
Laboratory tests
Thyroid ultrasonography
Fine-needle aspiration biopsy (FNAB)
The beneficial role of scintigraphy is limited. [11, 9] However, molecular marker analysis of FNAB samples is proving to be beneficial in determining surgical plans.
Most childhood thyroid nodules are asymptomatic and are detected by parents or by physicians during routine examination. Only about 50% of children with thyroid carcinoma present with nodular thyroid enlargement as the presenting symptom. Follicular adenoma is the most common cause of solitary thyroid nodules in the pediatric population; however, solitary nodules in children reportedly have a 20-73% incidence of malignancy. [12, 13, 14] A painless noninflammatory metastatic cervical mass is the presenting symptom in 40-80% of patients. [15] Malignant lesions are usually papillary and follicular carcinomas. Radiation exposure, which is still used either as therapy prior to bone marrow transplantation or as a treatment of Hodgkin disease, remains a major risk factor. [16]
The subsequent diagnostic workup is aimed at determining whether the lesion represents a malignancy. Collected data can be useful in preoperative planning if surgery is indicated. Pediatric and adult thyroid cancers have differing biological behaviors. Despite the fact that pediatric thyroid cancer usually presents at an advanced stage, it carries an excellent prognosis, with long-term survival rates greater than 95%.
An image depicting thyroid cancer can be seen below.
Radioactive therapy with iodine 131 (131I) is indicated to ablate residual normal thyroid and to treat functioning metastases in differentiated thyroid tumors. Because pediatric patients are few and the prognosis is generally excellent, 131I is usually recommended only for patients with extensive unresectable cervical nodal involvement, invasion of vital structures, or distant metastases. Very few instances of solid tumors or leukemia associated with 131I treatment have been reported. [17]
Treatment for thyroid malignancy is primarily surgical. Because of the unusual combination of an excellent prognosis and an advanced-stage disease presentation, the initial extent of surgery is controversial. Some recommend that the initial surgical approach be conservative, while others advocate aggressive management with total thyroidectomy and radioactive iodine (RAI) for all patients. The relative infrequency of thyroid malignancy makes this controversy difficult to resolve.
Thyroid lobectomy is the initial procedure of choice for most solitary thyroid lesions. The need for total versus near-total or subtotal thyroidectomy is controversial. Proponents for near-total or subtotal thyroidectomy believe that these procedures decrease the incidence of complications such as recurrent nerve injury and parathyroid devascularization, although the need to identify and preserve these structures remains. [18]
Although total thyroidectomy has not been proven to decrease recurrence, supporters of this method argue that remaining thyroid tissue may interfere with the use of radioactive iodine (RAI) in the postoperative diagnostic scanning and in the treatment of microscopic regional and distant disease. Total thyroidectomy and central neck dissection are indicated for biopsy-proven medullary carcinoma.
Selective ipsilateral neck dissection in pediatric thyroid surgery is indicated for proven or suspected regional lymph node metastasis.
As mentioned, in 2015 the American Thyroid Association (ATA) issued guidelines for the management of children with thyroid nodules and differentiated thyroid cancer. The guidelines’ 34 recommendations include the following, which have a recommendation rating of A [1, 2] :
For pediatric patients with a suppressed thyroid-stimulating hormone (TSH) associated with a thyroid nodule, thyroid scintigraphy should be pursued
A comprehensive neck ultrasonogram to interrogate all regions of the neck is required in order to optimize the preoperative surgical plan in children with a newly diagnosed papillary thyroid cancer
For the majority of children with papillary thyroid cancer, total thyroidectomy is recommended
In order to facilitate 131I uptake by residual iodine-avid cancer, the TSH should be above 30 mIU/L
Neck ultrasonography is recommended in the follow-up of children with papillary thyroid cancer; it should be performed at least 6 months after initial surgery and then at 6-12 month intervals for ATA pediatric intermediate- and high-risk patients and at annual intervals for ATA pediatric low-risk patients; follow-up beyond 5 years should be individualized based on recurrence risk
United States
Thyroid cancer, the most common pediatric endocrine neoplasm, represents 3% of all pediatric malignancies and 5-5.7% of malignancies in the head and neck. Only 5% of all thyroid cancers occur in children and adolescents. [19] Thyroid nodules occur in up to 35% of the general adult population and in only 1-2% of the pediatric population. These numbers are estimated using a compilation of data from multiple reports. [16, 20, 21]
Paradoxically, despite the lower incidence of thyroid nodules in children, a pediatric thyroid nodule has a greater risk of containing or developing a malignancy. Whereas 5% of nodules in adults are malignant, in the pediatric population, the percentage of malignant nodules is 26.4%. [8] The incidence of malignancy in multinodular goiter is 1-7% and 10-25% in solitary nodules. [16] Pediatric thyroid cancer (3% prevalence) in adolescents is also associated with juvenile autoimmune thyroiditis. [22]
A study by Bernier et al found that in the United States, between 1998 and 2013, the rate of pediatric differentiated thyroid cancer significantly increased among individuals aged 0 to 19 years, rising by 4.43% per year. This increase was seen in both sexes, with the rates rising in non-Hispanic whites, non-Hispanic blacks, and Hispanics. With regard to cancer stage, the annual rate increases for localized, regional, and distant tumors were 4.06%, 5.68%, and 8.55%, respectively, with the yearly increases for tumors less than 1 cm, 1-2 cm, and over 2 cm in size being 9.46%, 6.92%, and 4.69%. Owing to the climb in large and late-stage differentiated thyroid cancer rates, the investigators suggested that improved medical surveillance cannot entirely account for the changes. [23]
Using the US Cancer Statistics database, a study by Siegel et al found that in the United States, the overall incidence of pediatric thyroid carcinoma increased between 2003 and 2019, the average annual percentage change (AAPC) being 4.2%. In adolescents (ages 15-19 years), thyroid carcinoma was one of the most common of the International Classification of Childhood Cancer (ICCC) types, with a rate of 25.9 per million people (age adjusted to the 2000 US standard population) and an AAPC of 4.5%. The investigators suggested that the rise in pediatric thyroid carcinoma may have derived from overdiagnosis in addition to an actual increase in incidence stemming from various causes (eg, environmental exposures, such as ionizing radiation). [24]
Papillary thyroid cancer is by far the common thyroid malignancy in children, constituting 83% of all pediatric thyroid malignancies. [25] Although papillary carcinoma is more aggressive in children than in adults, pediatric papillary cancer carries a much better prognosis that adult thyroid cancer. [26]
Medullary thyroid cancer (MTC), which constitutes 5% of pediatric thyroid malignancies, is usually associated with multiple endocrine neoplasia type 2 (MEN2) in the pediatric population. The inheritance pattern occurs either sporadically or as familial MTC without other associated endocrine abnormalities. MEN2 consists of MTC and pheochromocytoma and either hyperparathyroidism (2A) or mucosal neuromas (2B). MTC associated with MEN2B is more virulent and may occur and metastasize early in infancy.
International
After the Chernobyl nuclear power plant disaster, individuals living in Russia, Ukraine, and Eastern Europe were exposed to significant levels of radioactive iodines, primarily iodine 131 (131 I). This radioactivity, which is concentrated in the thyroid gland, has resulted in a substantial increase in pediatric thyroid cancer rates among this cohort of children. [27, 28]
Pediatric thyroid malignancies are usually a well-differentiated papillary subtype or the papillary-follicular subtype, but all histologic types have been observed. Children commonly present with advanced disease. At presentation, 70% of patients have extensive regional nodal involvement, and 10-20% of patients have distant metastasis. [10] The lungs are the most common sites of metastasis.
Pediatric patients seem to have higher local and distant recurrence rates than adults, but they tend to respond rapidly to therapy. The prognosis for children is excellent, with mortality rates of less than 10%. [29] Benign tumors such as follicular adenomas should be considered at risk for tumor progression toward follicular thyroid carcinoma, and they must be surgically addressed. [8]
A retrospective study by Gruszczynski et al found that although 2- and 5-year overall and disease-specific survival in pediatric thyroid cancer was close to 100% in the report’s patients, various factors, including male sex, non-Caucasian race, poverty, and language isolation, were associated with worse overall survival in these persons. Moreover, male and Black pediatric patients were more likely to present with a higher overall American Joint Committee on Cancer (AJCC) stage. [30]
Thyroid carcinoma is 2-3 times more common in females. [31]
The gender distribution of thyroid carcinoma differs between adults and children. Thyroid cancer is 4 times as common in women as in men. This difference is not seen in individuals younger than 15 years; the girl-boy ratio is as low as 1.5:1. However, in individuals aged 15–20 years, the female-to-male ratio is 3:1. [32] This implies that female sex hormones, especially during puberty, play a significant yet still undefined role in the increased incidence of thyroid cancer in females. [19]
Age is a major determinant of both the incidence and recurrence of pediatric thyroid carcinoma. Pediatric thyroid carcinoma occurs more frequently in adolescents, although it has been reported in the neonatal period. [33] In children younger than 10 years, identified thyroid lesions are more likely to be malignant. [34] Children younger than 10 years are also more likely to have recurrent cancer. [29]
[Guideline] Francis G, Waguespack SG, Bauer AJ, et al. Management Guidelines for Children with Thyroid Nodules and Differentiated Thyroid Cancer The American Thyroid Association Guidelines Task Force on Pediatric Thyroid Cancer. Thyroid. 2015 Apr 21. [QxMD MEDLINE Link]. [Full Text].
Busko M. ATA Issues First Advice for Thyroid Nodules, Cancer in Children. Medscape Medical News. Apr 27 2015. [Full Text].
PDQ Pediatric Treatment Editorial Board. Childhood Thyroid Cancer Treatment (PDQ®): Patient Version. PDQ Cancer Information Summary. 2019 Mar 15. [QxMD MEDLINE Link]. [Full Text].
Corrias A, Mussa A. Thyroid Nodules in Pediatrics: Which Ones Can Be Left Alone, Which Ones Must be Investigated, When and How. J Clin Res Pediatr Endocrinol. 2013 March. 5(Suppl 1):57–69. [QxMD MEDLINE Link].
Silverman SH, Nussbaum M, Rausen AR. Thyroid nodules in children: a ten year experience at one institution. Mt Sinai J Med. 1979 Sep-Oct. 46(5):460-3. [QxMD MEDLINE Link].
Ridgway EC. Clinician Evaluation of a Solitary Thyroid Nodules. Journal of Clinical Endocrinology and Metaoblism. 1992. Vol. 74, No. 2:231-235.
Skinner MA, Wells SA Jr. Medullary carcinoma of the thyroid gland and the MEN 2 syndromes. Semin Pediatr Surg. 1997 Aug. 6(3):134-40. [QxMD MEDLINE Link].
Niedziela M. Pathogenesis, diagnosis and management of thyroid nodules in children. Endocr Relat Cancer. 2006 Jun. 13(2):427-53. [QxMD MEDLINE Link].
Halac I, Zimmerman D. Thyroid nodules and cancers in children. Endocrinol Metab Clin North Am. 2005 Sep. 34(3):725-44, x. [QxMD MEDLINE Link].
Yoskovitch A, Laberge JM, Rodd C, et al. Cystic thyroid lesions in children. J Pediatr Surg. 1998 Jun. 33(6):866-70. [QxMD MEDLINE Link].
Niedziela M, Korman E. Thyroid carcinoma in a fourteen-year-old boy with Graves disease. Med Pediatr Oncol. 2002 Apr. 38(4):290-1. [QxMD MEDLINE Link].
Festen C, Otten BJ, van de Kaa CA. Follicular adenoma of the thyroid gland in children. Eur J Pediatr Surg. 1995 Oct. 5(5):262-4. [QxMD MEDLINE Link].
Schneider K. Sonographic imaging of the thyroid in children. Prog Pediatr Surg. 1991. 26:1-14. [QxMD MEDLINE Link].
Sherman NH, Rosenberg HK, Heyman S, et al. Ultrasound evaluation of neck masses in children. J Ultrasound Med. 1985 Mar. 4(3):127-34. [QxMD MEDLINE Link].
Dinauer CA, Breuer C, Rivkees SA. Differentiated thyroid cancer in children: diagnosis and management. Curr Opin Oncol. 2008 Jan. 20(1):59-65. [QxMD MEDLINE Link].
Garcia CJ, Daneman A, Thorner P, et al. Sonography of multinodular thyroid gland in children and adolescents. Am J Dis Child. 1992 Jul. 146(7):811-6. [QxMD MEDLINE Link].
Yeh SD, La Quaglia MP. 131I therapy for pediatric thyroid cancer. Semin Pediatr Surg. 1997 Aug. 6(3):128-33. [QxMD MEDLINE Link].
Herzog B. Thyroid gland diseases and tumours. Surgical aspects. Prog Pediatr Surg. 1983. 16:15-22. [QxMD MEDLINE Link].
Rapkin L, Pashankar FD. Management of thyroid carcinoma in children and young adults. J Pediatr Hematol Oncol. 2012 May. 34 Suppl 2.:S39-46. [QxMD MEDLINE Link].
Khurana KK, Labrador E, Izquierdo R, et al. The role of fine-needle aspiration biopsy in the management of thyroid nodules in children, adolescents, and young adults: a multi-institutional study. Thyroid. 1999 Apr. 9(4):383-6. [QxMD MEDLINE Link].
Lugo-Vicente H, Ortiz VN, Irizarry H, et al. Pediatric thyroid nodules: management in the era of fine needle aspiration. J Pediatr Surg. 1998 Aug. 33(8):1302-5. [QxMD MEDLINE Link].
Corrias A, Cassio A, Weber G, et al. Thyroid nodules and cancer in children and adolescents affected by autoimmune thyroiditis. Arch Pediatr Adolesc Med. 2008 Jun. 162(6):526-31. [QxMD MEDLINE Link].
Bernier MO, Withrow DR, Berrington de Gonzalez A, et al. Trends in pediatric thyroid cancer incidence in the United States, 1998-2013. Cancer. 2019 Apr 23. [QxMD MEDLINE Link].
Siegel DA, King JB, Lupo PJ, et al. Counts, incidence rates, and trends of pediatric cancer in the United States, 2003-2019. J Natl Cancer Inst. 2023 Jul 11. [QxMD MEDLINE Link]. [Full Text].
Zimmerman, D. Thyroid Carcinoma in Children and Adolescents: diagnostic implications of analysis of the tumor genome. Curr Opin Pediatr. 25:[QxMD MEDLINE Link].
Miccoli P, Minuto MN, Ugolini C, et al. Papillary thyroid cancer: pathological parameters as prognostic factors in different classes of age. Otolaryngol Head Neck Surg. 2008 Feb. 138(2):200-3. [QxMD MEDLINE Link].
Williams ED, Abrosimov A, Bogdanova T, et al. Thyroid carcinoma after Chernobyl latent period, morphology and aggressiveness. Br J Cancer. 2004 Jun 1. 90(11):2219-24. [QxMD MEDLINE Link].
Ron E. Thyroid cancer incidence among people living in areas contaminated by radiation from the Chernobyl accident. Health Phys. 2007 Nov. 93(5):502-11. [QxMD MEDLINE Link].
Alessandri AJ, Goddard KJ, Blair GK, et al. Age is the major determinant of recurrence in pediatric differentiated thyroid carcinoma. Med Pediatr Oncol. 2000 Jul. 35(1):41-6. [QxMD MEDLINE Link].
Gruszczynski NR, Low CM, Choby G, Meister KD, Smith BH, Balakrishnan K. Effects of Social Determinants of Health Care on Pediatric Thyroid Cancer Outcomes in the United States. Otolaryngol Head Neck Surg. 2021 Jul 27. 1945998211032901. [QxMD MEDLINE Link].
La Quaglia MP, Telander RL. Differentiated and medullary thyroid cancer in childhood and adolescence. Semin Pediatr Surg. 1997 Feb. 6(1):42-9. [QxMD MEDLINE Link].
Attie JA. Carcinoma of the thyroid in children and adolescents. F Lifshitz. Pediatric Endocrinology. 3. New York: Marcel Dekker; 1996. 423-432.
Estevao-Costa J, Gil-Da-Costa MJ, Medina AM, et al. Thyroid carcinoma in a newborn: clinical challenges in managing the first recorded case. Med Pediatr Oncol. 2000 Apr. 34(4):290-2. [QxMD MEDLINE Link].
Yip FW, Reeve TS, Poole AG, et al. Thyroid nodules in childhood and adolescence. Aust N Z J Surg. 1994 Oct. 64(10):676-8. [QxMD MEDLINE Link].
Cotterill SJ, Pearce MS, Parker L. Thyroid cancer in children and young adults in the North of England. Is increasing incidence related to the Chernobyl accident?. Eur J Cancer. 2001 May. 37(8):1020-6. [QxMD MEDLINE Link].
Gawrysiak W, Niedziela M. Suppurative thyroiditis. Endokrynologia Pediatryczna (Pediatric Endocrinology). 2005. 4:65-69.
Bhatia S, Ramsay NK, Bantle JP, et al. Thyroid Abnormalities after Therapy for Hodgkin’s Disease in Childhood. Oncologist. 1996. 1(1 & 2):62-67. [QxMD MEDLINE Link].
Jensen MO, Antonenko D. Thyroid and thymic malignancy following childhood irradiation. J Surg Oncol. 1992 Jul. 50(3):206-8. [QxMD MEDLINE Link].
Metayer C, Lynch CF, Clarke EA, et al. Second cancers among long-term survivors of Hodgkin’s disease diagnosed in childhood and adolescence. J Clin Oncol. 2000 Jun. 18(12):2435-43. [QxMD MEDLINE Link].
Nikiforov Y, Gnepp DR. Pediatric thyroid cancer after the Chernobyl disaster. Pathomorphologic study of 84 cases (1991-1992) from the Republic of Belarus. Cancer. 1994 Jul 15. 74(2):748-66. [QxMD MEDLINE Link].
Vane D, King DR, Boles ET Jr. Secondary thyroid neoplasms in pediatric cancer patients: increased risk with improved survival. J Pediatr Surg. 1984 Dec. 19(6):855-60. [QxMD MEDLINE Link].
Thomas GA, Bunnell H, Cook HA, et al. High prevalence of RET/PTC rearrangements in Ukrainian and Belarussian post-Chernobyl thyroid papillary carcinomas: a strong correlation between RET/PTC3 and the solid-follicular variant. J Clin Endocrinol Metab. 1999 Nov. 84(11):4232-8. [QxMD MEDLINE Link].
Sklar C, Whitton J, Mertens A, et al. Abnormalities of the thyroid in survivors of Hodgkin’s disease: data from the Childhood Cancer Survivor Study. J Clin Endocrinol Metab. 2000 Sep. 85(9):3227-32. [QxMD MEDLINE Link].
Patti G, Ragni G, Calisti A. Papillary thyroid carcinoma in a thyroglossal duct cyst in a child. Med Pediatr Oncol. 2000 Jan. 34(1):67-9. [QxMD MEDLINE Link].
Luboshitzky R, Lavi I, Ishay A. Serum thyroglobulin levels after fine-needle aspiration of thyroid nodules. Endocr Pract. 2006 May-Jun. 12(3):264-9. [QxMD MEDLINE Link].
Bockhorn M, Frilling A, Rewerk S, et al. Lack of elevated serum carcinoembryonic antigen and calcitonin in medullary thyroid carcinoma. Thyroid. 2004 Jun. 14(6):468-70. [QxMD MEDLINE Link].
Telander RL, Moir CR. Medullary thyroid carcinoma in children. Semin Pediatr Surg. 1994 Aug. 3(3):188-93. [QxMD MEDLINE Link].
Bajpai M, Ramaswamy S, Gupta DK, et al. Solitary thyroid nodule. Indian Pediatr. 1992 Jan. 29(1):116-8. [QxMD MEDLINE Link].
Solbiati L, Cioffi V, Ballarati E. Ultrasonography of the neck. Radiol Clin North Am. 1992 Sep. 30(5):941-54. [QxMD MEDLINE Link].
Lim-Dunham JE, Erdem Toslak I, Alsabban K, et al. Ultrasound risk stratification for malignancy using the 2015 American Thyroid Association Management Guidelines for Children with Thyroid Nodules and Differentiated Thyroid Cancer. Pediatr Radiol. 2017 Apr. 47 (4):429-36. [QxMD MEDLINE Link].
Hegedüs L, Bonnema SJ, Bennedbaek FN. Management of simple nodular goiter: current status and future perspectives. Endocr Rev. 2003 Feb. 24(1):102-32. [QxMD MEDLINE Link].
Harach HR, Sanchez SS, Williams ED. Pathology of the autonomously functioning (hot) thyroid nodule. Ann Diagn Pathol. 2002 Feb. 6(1):10-9. [QxMD MEDLINE Link].
Croom RD 3rd, Thomas CG Jr, Reddick RL, et al. Autonomously functioning thyroid nodules in childhood and adolescence. Surgery. 1987 Dec. 102(6):1101-8. [QxMD MEDLINE Link].
Geiger JD, Thompson NW. Thyroid tumors in children. Otolaryngol Clin North Am. 1996 Aug. 29(4):711-9. [QxMD MEDLINE Link].
Desjardins JG, Khan AH, Montupet P, et al. Management of thyroid nodules in children: a 20-year experience. J Pediatr Surg. 1987 Aug. 22(8):736-9. [QxMD MEDLINE Link].
Eisenhut CC, King DE, Nelson WA, et al. Fine-needle biopsy of pediatric lesions: a three-year study in an outpatient biopsy clinic. Diagn Cytopathol. 1996 Feb. 14(1):43-50. [QxMD MEDLINE Link].
Raab SS, Silverman JF, Elsheikh TM, et al. Pediatric thyroid nodules: disease demographics and clinical management as determined by fine needle aspiration biopsy. Pediatrics. 1995 Jan. 95(1):46-9. [QxMD MEDLINE Link].
Bettendorf M. Thyroid disorders in children from birth to adolescence. Eur J Nucl Med Mol Imaging. 2002 Aug. 29 Suppl 2:S439-46. [QxMD MEDLINE Link].
Gimm O, Sutter T, Dralle H. Diagnosis and therapy of sporadic and familial medullary thyroid carcinoma. J Cancer Res Clin Oncol. 2001. 127(3):156-65. [QxMD MEDLINE Link].
Dinauer CA, Breuer C, Rivkees SA. Differentiated thyroid cancer in children: diagnosis and management. Curr Opin Oncol. 2008 Jan. 20(1):59-65. [QxMD MEDLINE Link].
AJCC Cancer Staging Manual. Sixth Edition. New York: Springer-Verlag, , Inc; 2002.
Retevmo (selpercatinib) [package insert]. Indianapolis, IN: Eli Lilly and Company. 2020 May. Available at [Full Text].
Bryarly RC, Shockley WW, Stucker FJ. The method and management of thyroid surgery in the pediatric patient. Laryngoscope. 1985 Sep. 95(9 Pt 1):1025-8. [QxMD MEDLINE Link].
Lallier M, St-Vil D, Giroux M, et al. Prophylactic thyroidectomy for medullary thyroid carcinoma in gene carriers of MEN2 syndrome. J Pediatr Surg. 1998 Jun. 33(6):846-8. [QxMD MEDLINE Link].
Newman KD, Black T, Heller G, et al. Differentiated thyroid cancer: determinants of disease progression in patients Ann Surg</i>. 1998 Apr. 227(4):533-41. [QxMD MEDLINE Link].
Yap A, Shui A, Gosnell J, Huang CY, Sosa JA, Roman S. Accuracy of the Lymph Node Yield in Surgery for Papillary Thyroid Cancer in Children. World J Surg. 2021 Jun 27. [QxMD MEDLINE Link].
Ben Arush MW, Stein ME, Perez Nahum M, et al. Pediatric thyroid carcinoma: 22 years of experience at the Northern Israel Oncology Center (1973-1995). Pediatr Hematol Oncol. 2000 Jan-Feb. 17(1):85-92. [QxMD MEDLINE Link].
Baumgarten HD, Bauer AJ, Isaza A, Mostoufi-Moab S, Kazahaya K, Adzick NS. Surgical management of pediatric thyroid disease: complication rates after thyroidectomy at the Children’s Hospital of Philadelphia high-volume Pediatric Thyroid Center. J Pediatr Surg. 2019 Feb 28. [QxMD MEDLINE Link].
Mark E Gerber, MD Clinical Associate Professor of Surgery, University of Chicago Pritzker School of Medicine; Division Head, Otolaryngology-Head and Neck Surgery; Director, Pediatric Otolaryngology-Head and Neck Surgery, NorthShore University Health System

Mark E Gerber, MD is a member of the following medical societies: American Academy of Otolaryngology-Head and Neck Surgery, American Bronchoesophagological Association, American Society of Pediatric Otolaryngology, Society for Ear, Nose and Throat Advances in Children, American Academy of Pediatrics, American Rhinologic Society

Disclosure: Nothing to disclose.
Brian Kip Reilly, MD Associate Professor of Otolaryngology and Pediatrics, Department of Otolaryngology, Children’s National Medical Center, George Washington University School of Medicine

Brian Kip Reilly, MD is a member of the following medical societies: American Academy of Otolaryngology-Head and Neck Surgery

Disclosure: Nothing to disclose.
Mihir K Bhayani, MD Clinical Assistant Professor, Department of Surgery, University of Chicago Division of the Biological Sciences, The Pritzker School of Medicine; Consulting Surgeon, Head and Neck Surgical Oncology Section, Department of Otolaryngology, NorthShore University Health System

Mihir K Bhayani, MD is a member of the following medical societies: American Head and Neck Society

Disclosure: Nothing to disclose.
Francisco Talavera, PharmD, PhD Adjunct Assistant Professor, University of Nebraska Medical Center College of Pharmacy; Editor-in-Chief, Medscape Drug Reference

Disclosure: Received salary from Medscape for employment. for: Medscape.
Nader Sadeghi, MD, FRCSC Professor and Chairman, Department of Otolaryngology-Head and Neck Surgery, McGill University Faculty of Medicine; Chief Otolaryngologist, MUHC; Director, McGill Head and Neck Cancer Program, Royal Victoria Hospital, Canada

Nader Sadeghi, MD, FRCSC is a member of the following medical societies: American Academy of Otolaryngology-Head and Neck Surgery, American Head and Neck Society, American Thyroid Association, Royal College of Physicians and Surgeons of Canada

Disclosure: Nothing to disclose.
Arlen D Meyers, MD, MBA Emeritus Professor of Otolaryngology, Dentistry, and Engineering, University of Colorado School of Medicine

Arlen D Meyers, MD, MBA is a member of the following medical societies: American Academy of Facial Plastic and Reconstructive Surgery, American Academy of Otolaryngology-Head and Neck Surgery, American Head and Neck Society

Disclosure: Serve(d) as a director, officer, partner, employee, advisor, consultant or trustee for: Cerescan; Neosoma; MI10;<br/>Received income in an amount equal to or greater than $250 from: Neosoma; Cyberionix (CYBX)<br/>Received ownership interest from Cerescan for consulting for: Neosoma, MI10 advisor.
Russell A Faust, MD, PhD Consulting Staff, Department of Otolaryngology, Columbus Children’s Hospital
Disclosure: Nothing to disclose.

source

Leave a Comment